SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ferlay J,Bray F,Pisani P,Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. Vol. 2005. Lyon: IARC Press; 2004.
  • 2
    American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed August 17, 2007.
  • 3
    Henschke CI,Yankelevitz DF,Libby DM,Pasmantier MW,Smith JP,Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355: 17631771.
  • 4
    Bach PB,Jett JR,Pastorino U,Tockman MS,Swensen SJ,Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007; 297: 953961.
  • 5
    Gohagan J,Marcus P,Fagerstrom R,Pinsky P,Kramer B,Prorok P. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest. 2004; 126: 114121.
  • 6
    van Iersel CA,de Koning HJ,Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007; 120: 868874.
  • 7
    Welch HG,Woloshin S,Schwartz LM, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med. 2007; 167: 22892295.
  • 8
    UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. Available at URL: http://www.nsc.nhs.uk/pdfs/criteria.pdf. Accessed June 12, 2007.
  • 9
    de Haes JC,de Koning HJ,van Oortmarssen GJ,van Agt HM,de Bruyn AE,van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991; 49: 538544.
  • 10
    Essink-Bot ML,Korfage IJ,De Koning HJ. Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited? BJU Int. 2003; 92( suppl 2): 101105.
  • 11
    Xu DM,Gietema H,de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006; 54: 177184.
  • 12
    Essink-Bot ML,Rijnsburger AJ,van Dooren S,de Koning HJ,Seynaeve C. Women's acceptance of MRI in breast cancer surveillance because of a familial or genetic predisposition. Breast. 2006; 15: 673676.
  • 13
    Kruijshaar ME,Kerkhof M,Siersema PD,Steyerberg EW,Homs MY,Essink-Bot ML. The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Endoscopy. 2006; 38: 873878.
  • 14
    Essink-Bot ML,de Koning HJ,Nijs HG,Kirkels WJ,van der Maas PJ,Schroder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst. 1998; 90: 925931.
  • 15
    Khanna D,Tsevat J. Health-related quality of life–an introduction. Am J Manag Care. 2007; 13( suppl 9): S218S223.
  • 16
    McCaffery KJ,Barratt AL. Assessing psychosocial/quality of life outcomes in screening: how do we do it better? J Epidemiol Community Health. 2004; 58: 968970.
  • 17
    Essink-Bot ML,Stouthard ME,Bonsel GJ. Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Econ. 1993; 2: 237246.
  • 18
    Gandek B,Ware JE,Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in 9 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998; 51: 11711178.
  • 19
    Kind P,Brooks R,Rabin R. EQ-5D concepts and methods: a development history. Dordrecht, the Netherlands: Springer; 2005.
  • 20
    Ware JJr,Kosinski M,Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34: 220233.
  • 21
    Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997; 35: 10951108.
  • 22
    van der Bij AK,de Weerd S,Cikot RJ,Steegers EA,Braspenning JC. Validation of the dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. Community Genet. 2003; 6: 8487.
  • 23
    Brom D,Kleber RJ. De Schok Verwerkings Lijst [The Dutch version of the Impact of Event Scale]. Nederlands Tijdschrift voor de Psychologie. 1985; 40: 164168.
  • 24
    Horowitz M,Wilner N,Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979; 41: 209218.
  • 25
    Mudde AN,Willemsen MC,Kremers S,De Vries H. Meetinstrumenten voor onderzoek naar roken en stoppen met roken [Measurement Instruments used in Research with Regard to Smoking and Smoking Cessation]. 2nd ed. The Hague: STIVORO; 2006. Available from URL: http://www.stivoro.nl/upload/_publdocs/meetinstrumenten_3.pdf. Accessed October 8, 2006.
  • 26
    Statistic Netherlands. Statline. Available at URL: http://statline.cbs.nl. 2005. Accessed May 8, 2007.
  • 27
    Van der Ploeg HM,Defares PB,Spielberger CD. Handleiding bij de Zelf-Beoordelings Vragenlijst ZBV [Manual for the Dutch Adaptation of the STAI-Y]. Lisse, the Netherlands: Swets & Zeitlinger; 1980.
  • 28
    Norman GR,Sloan JA,Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582592.
  • 29
    Cullen J,Schwartz MD,Lawrence WF,Selby JV,Mandelblatt JS. Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol. 2004; 22: 943952.
  • 30
    Rijnsburger AJ,Essink-Bot ML,van Dooren S, et al. Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer. 2004; 91: 6976.
  • 31
    Taylor KL,Shelby R,Gelmann E,McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst. 2004; 96: 10831094.
  • 32
    Laaksonen M,Rahkonen O,Martikainen P,Karvonen S,Lahelma E. Smoking and SF-36 health functioning. Prev Med. 2006; 42: 206209.
  • 33
    Otto SJ,Schroder FH,de Koning HJ. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen. 2004; 11: 8992.
  • 34
    Folkman S. Positive psychological states and coping with severe stress. Soc Sci Med. 1997; 45: 12071221.
  • 35
    Brodersen J,Thorsen H,Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. J Med Screen. 2004; 11: 3944.
  • 36
    Barton MB,Morley DS,Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. JNatl Cancer Inst. 2004; 96: 529538.
  • 37
    Brodersen J,Thorsen H,Kreiner S. Validation of a condition-specific measure for women having an abnormal screening mammography. Value Health. 2007; 10: 294304.